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 CURRENTOPINION Hypothermic liver perfusion
Andrea Schlegela,b, Xavier Mullerc, and Philipp Dutkowskic
Purpose of review
The review describes recent developments in hypothermic machine liver perfusion with a special focus on
underlying protective mechanisms, and the role of this perfusion technique in high-risk donor–recipient
combinations.
Recent findings
To maximize the number of transplantable donor livers, several centres are exploring new machine
preservation techniques. In this context, hypothermic machine perfusion has been recently introduced into
the clinical setting of human liver transplantation, and the effect of endischemic cold liver perfusion on
posttransplant complications is currently under investigation in two multicentre, randomized controlled trials.
In addition, current case series demonstrated promising results regarding the protection from intrahepatic
biliary complications, particularly when livers from extended criteria donors including donation after
circulatory death grafts were used. Hypothermic machine perfusion may, therefore, help to push the
boundaries of acceptance criteria for high-risk donor livers.
Summary
In this review, we, first, describe the concept of hypothermic machine liver perfusion and present results from
current clinical studies. Next, we provide details of our perfusion approach step-by-step and highlight novel
pathways of reperfusion injury and protection. Third, we discuss the impact of this perfusion approach in
different clinical scenarios. Finally, we report on recent clinical implementations and future aspects.
Keywords
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INTRODUCTION
Given the shortage of available and suitable organs,
transplant physicians are forced to use extended cri-
teria donors (ECD) livers, for example, elderly and
steatotic allografts, and organs from donation after
circulatory death donors (DCD) [1,2]. Consistently,
we observed a shift toward extended and even ‘over-
extended’, or so called high-risk donor livers, fre-
quently offered for transplantation in our aging
population [3]. Of note, therefore, the ‘standard’ liver
today would have been similarly classified as
‘extended’ in thepast [4]. Suchorgans,however, carry
an increased risk forprimarynonfunction (PNF), early
allograft dysfunction (EAD), and intrahepatic biliary
complications,with impaired long-termsurvival rates
[1]. An aggressive usage of higher risk grafts remains
yet limited, in spite of organ shortage [5]. Based on
this, the transplant community is interested to eval-
uate the impact of new technologies, for example,
machineperfusion, onoutcomeafter implantationof
high-risk liver grafts. Viability assessment and predic-
tion of graft function are the two challenges to reduce
discard rates, and to facilitate well tolerated trans-
plants in the future.
The review focuses, first, on the concept of
hypothermic machine perfusion (HMP). Second,
wewill summarize underlyingmechanisms of injury
and protection. Third, recent clinical studies are
discussed together with the impact of HMP in the
context of special clinical situations, when high-risk
grafts are used. Finally, we highlight future aspects.
THE CONCEPT OF HYPOTHERMIC
MACHINE LIVER PERFUSION
The use of ex-vivomachine perfusion remains inves-
tigational in clinical liver transplantation. In general,
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machine perfusion provides continuous circulation
of oxygen, nutrients, and other metabolic substrates
during a certain period (Fig. 1) [6]. Prior to 2010, the
majority of studies, which reported on machine per-
fusion, involved only animal models [7–12]. After
the first clinical case series of HMP in 2010 [13],
however, there has been a rapid development of this
technology in clinical settings in Europe and United
States [14–17,18
&
].Most clinical investigations target
outcomes after ex-vivomachine perfusion at various
temperatures using different perfusates and devices
[16,19–21]. Despite the overall clinical success of
endischemic HMP, optimal temperatures, oxygen
concentration, and perfusion protocols are a current
topic of debate [19,22,23].
HYPOTHERMIC OXYGENATED
PERFUSION TREATMENT: HOW WE DO IT
Our concept of HMP has been introduced into clini-
cal practice in January 2011, when the national DCD
transplant program in Switzerland was reestablished
[15,24]. This implementation of HMP into the clinic
was preceded by over 20 years of basic research
[7,12,25–33]. Hypothermic oxygenated perfusion
(HOPE) at our centre is, therefore, routinely used
to improve the quality of DCD livers, from Maas-
tricht III donors and donation after brain death
(DBD) livers with prolonged cold storage and stea-
totic grafts (Figs. 1 and 2) [16,34
&
,35]. Following
withdrawal of treatment in theatre, donor cardiac
arrest is observed and a 10-min ‘hand-off’ period is
maintained [6]. In next step, brain death is con-
firmed by our consultant neurologist. Importantly,
such scenario leads to a prolonged median total,
functional and asystolic donor warm ischemia of 38,
31, and 17min, respectively, in our DCD cohort
(Table 1) [16,36]. No additional heparin is adminis-
tered to donors before declaration of death. Super
rapid cannulation is achieved by laparotomy and
insertion of a double balloon catheter into the
infrarenal aorta or iliac artery with blocking of the
supraceliac aorta. Subsequently, we cut the iliac vein
for decompression, and start flushing abdominal
organs first with 2 l of heparinized saline at room
temperature. Afterwards, cold flush is initiated with
cooled Institute George Lopez-1 solution (pre-
cooled; Fig. 2). During abdominal flush, sternotomy
is performed, and the thoracic organs are prepared
and procured by the thoracic team. Afterwards, we
resect liver, pancreas, and kidneys. Following hepa-
tectomy, and prior to organ packing and transport,
an additional liver flush through the hepatic artery,
portal vein, and the biliary system is routinely per-
formed (bench procedure in donor centre, Fig. 2).
Importantly, the gallbladder is always opened
already prior to hepatectomy to flush out poten-
tially toxic bile [37,38]. In the recipient centre, we
perform an additional flush through hepatic artery,
portal vein, and the biliary system. Following bench
KEY POINTS
 HMP is a valuable tool to improve liver graft quality
prior to normothermic reperfusion and transplantation.
 Endischemic HOPE restores cellular energy levels,
protects mitochondria from injury during reperfusion,
and consequently reduces ROS release
and inflammation.
 HOPE treatment prevents development of PNFs and
intrahepatic ischemic cholangiopathy in extended
human DCD livers.
 Better biomarkers are currently under investigation to
predict perfusion duration and later graft function after
implantation of HOPE-treated livers.
FIGURE 1. HOPE of extended human DCD livers prior to implantation. HOPE perfusion, performed in human DCD liver grafts of
different risk profile prior to implantation. (a) ‘Normal’ DCD liver graft (>30-min fDWIT), (b): Steatotic DCD liver graft. DCD,
donation after circulatory death donors; fDWIT, functional donor warm ischemia time; HOPE, hypothermic oxygenated perfusion.
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procedure at the transplant centre, we connect the
liver to a pressure controlled Liver Assist device
(Organ Assist, Groningen The Netherlands), using
a curved cannula (Groningen The Netherlands),
which is inserted into the portal vein and secured
by silk ties (Fig. 2). HOPE is then applied through
the portal vein only, using highly oxygenated
(60–80 kPa) Belzer machine perfusion solution.
The perfusion pressure is limited to maximal
3mmHg, and permanently controlled by the device
to avoid additional endothelial injury [30]. Liver
treatment by HOPE is continued during recipient
hepatectomy for at least 1h, but generally until
implantation. Prior to HOPE we routinely obtain
a liver biopsy to quantify liver graft steatosis and
fibrosis. Under special conditions, for example,
when DCD liver grafts have additional steatosis,
we delay the start of the recipient surgery, to be
aware of the biopsy result and observe the liver
behaviour during HOPE. In addition to perfusion
flow and pressure, further parameters involve per-
fusate aspartate aminotransferase and alanine ami-
notransferase and oxygen consumption [15]. For
future measurements, we collect perfusate to run
absorbance and metabolomics analyses for investi-
gation of new biomarkers, which could help to
predict the required perfusion duration. Our group
has also analysed theperfusionquality of liver tissue
comparing the portal vein only approach with
a dual HOPE technique (through hepatic artery
and portal vein). As both techniques achieved an
equally well and homogenously perfused liver
within the first 5min of HOPE, including the extra-
hepatic bile duct, we believe currently that perfu-
sion through the hepatic artery is not advantageous
in the cold [15,39–42].
PROTECTIVE MECHANISM OF
HYPOTHERMIC OXYGENATED
PERFUSION
Normothermic reperfusion after ischemia leads to
injury in organs, defined as reperfusion injury [43].
Current data suggests an impact of the duration of
ischemia before reperfusion on subsequent cell
damage following reperfusion. Paradoxically, there-
fore, although ischemic cells need oxygen to sur-
vive, restoration of blood flow causes injury [44].
FIGURE 2. HOPE in Maastricht III DCD donor livers – How we do it. Detailed process of DCD liver donation, procurement,
bench procedure, and HOPE treatment, as performed at our centre. DCD, donation after circulatory death donors; HA,
hepatic artery; PV, portal vein; UW, University of Wisconsin; IGL-1, institute George Lopez-1 solution.
Hypothermic liver perfusion Schlegel et al.
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Themechanismbehindhas been recentlydiscov-
ered, and relates mainly to release of mitochondrial-
derived reactive oxygen species (ROS) during the
first minutes of normothermic reperfusion (Fig. 3)
[29,45–47]. The vast and initiating ROS are probably
delivered frommitochondrial complex I, and initiate
further injury by hydroxylation of cardiolipin, and
opening of the mitochondrial permeability transi-
tion pore together with disruption of the energy
producing electron transfer [25,30,44,48]. Themech-
anism of ROS release by complex I was recently
reported and was based on an unphysiologic reverse
electron flow (RET) between complex II and complex
I, caused by accumulation of succinate during ische-
mia in combination with a high protonmotive force
in the first minutes of reperfusion [49].
Mitochondrial ROS induce downstream inflam-
mationprocess, leading to release of danger-associated
molecular patterns and consecutively activation of
toll-like receptors on nonparenchymal liver cells
[34
&
]. Subsequently, an innate immune response con-
tributes to activation of lymphocytes and formation
of scar tissue by activation of stellate cells [50].
The protective effect of HOPE appears several
folded: first, during HOPE, we observed very low
levels of RET despite high levels of oxygen, probably
related to hypothermia-induced low proton-motive
forces. Second, HOPE leads to metabolism of
accumulated succinate and to significant upload of
ADP and ATP levels within 1–2h (Fig. 3) [17,31,34
&
].
Third, after HOPE treatment, electron donors
are decreased and high nucleotide levels restored
which leads to a reduced RET and less ROS release
during reperfusion [30,31,33,34
&
,51]. Numerous
downstream inflammation processes appear, there-
fore, decreased after transplantation of HOPE treated
liver grafts, including the immune response, result-
ing in less graft rejections in animal models and also
in human DCD liver transplants [32,36].
CLINICAL DATA
Several promising nonrandomized clinical studies
on HMP in liver transplantation have been pub-
lished over the past 3 years [14,16,17]. Although
some variability exists in the perfusion technique,
all clinical HMP series to date have reported
improved outcomes with reduction in EAD, biliary
complications, reduced hospital length of stay, and
improved graft survival [14,15,17,34
&
]. Following
the very first clinical application of hypothermic
dual perfusion (portal vein and hepatic artery) in
the 20 standard DBD human livers, the group
of James Guarerra reported recently that such per-
fusion approach appeared to be also protective in
marginal DBD (ECD) liver grafts [14].
FIGURE 3. Mechanism of injury following ischemia/reperfusion and protection through hypothermic machine perfusion
approaches. HOPE treatment provides a reconditioning of mitochondria prior to normothermic reperfusion. At the end of
HOPE, ADP and ATP have been recharged together with an increased metabolism of succinate. HOPE-treated livers are,
therefore, protected from ROS release, downstream mediator activation, and inflammation. HOPE-treated livers experience
consecutively significantly less PNF, less necrosis, and less chronic inflammation. Hmgb-1, high-mobility group box 1 protein;
HOPE, hypothermic oxygenated perfusion; KC, kupffer cell; PNF, primary nonfunction; RET, reverse electron flow; ROS,
reactive oxygen species; SEC, Sinusoidal endothelial cell; 8-OHdG, 8-hydroxy-2’-deoxyguanosine.
Hypothermic liver perfusion Schlegel et al.
1087-2418 Copyright  2017 Wolters Kluwer Health, Inc. All rights reserved. www.co-transplantation.com 567
 Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
Importantly, cold machine perfusion was
applied after cold storage and performed without
active oxygenation, but the perfusate contained
sufficient oxygen because of an open system with
contact to room air. Recipients in the perfusion
group experienced less biliary complication after
implantation of marginal DBD livers [14]. Consis-
tent with these results, HOPE treatment has been
shown by our group to be protective in extended
human DCD liver grafts, despite long donor warm
ischemia times, with no occurrence of intrahepatic
biliary complicationswhen comparedwithmatched
unperfused DCD livers [16].
Such results were recently paralleled by the
report from Groningen, where authors also showed
protection of human DCD livers in the Netherlands
(Table 1) [17]. In total, 10 human DCD livers were
perfused by dual HOPE and liver recipients were
protected from graft loss because of intrahepatic
biliary complications in contrast to 20 nonperfused
controls [17]. In addition, our group recently
reported the first 5-year outcome study with more
than 50 human DCD livers transplanted after HOPE
treatment [36]. Compared with matched, unper-
fused controls, HOPE livers developed significantly
less PNF, hepatic artery thrombosis, and impor-
tantly intrahepatic biliary complications (Table 1)
[36]. Although these reports lack randomization,
two randomized controlled trials are currently
on their way (hope-liver.com – Zurich, Groningen
Institute for Organ transplantation). In addition,
the impact of HOPE is explored in clinical and
experimental models of heart, lung, and kidney
transplantation [52–55].
The development of innovative portable
machine perfusion devices has opened the door
for a wider use of machine perfusion in other coun-
tries. In this context, a HOPE approach was recently
tested in Maastricht Type II DCD livers following
normothermic regional perfusion, and after
extended cold storage in Italy [18
&
,56].
WHICH LIVERS REQUIRE MACHINE
PERFUSION?
Liver injury already starts during brain death, and
increases with every day a potential organ donor
remains in the ICU [1]. Additional injury accumu-
lates throughout the entire process of organ
procurement, transport, bench preparation, and
implantation [1,6,37]. Although routine cold stor-
age has served as gold standard in organ preserva-
tion in the past, physicians become more and more
aware of the risk of cold storage for extended criteria
grafts, for example, steatotic, aged, or DCD livers [1].
The disadvantage of static preservation is related to
the lack of cellular energy and nutrients, leading to
continuous nucleotide breakdown, lactate acidosis,
calcium accumulation, calpain activation, and sinu-
soidal endothelial injury [51]. The maximum time
period, where cold storage can be safely applied is
therefore limited [7], but standard grafts cope rela-
tively well with 8–10h of cold static preservation.
In contrast, livers with additional previous
ischemia in donors, or livers that produce high
levels of acetyl CoA, for example, steatotic grafts,
trigger an overload of electron donors, and consec-
utively suffer from high levels of mitochondrial ROS
during reperfusion [47]. Such livers particularly ben-
efit from ex-vivo graft treatment to avoid significant
reperfusion injury [57,58]. Of note, many transplant
programs experience nowadays a shift toward more
marginal or ECD grafts, offered for transplantation
(Fig. 4) [4,59,60]. Machine perfusion could, there-
fore, contribute to optimize high-risk donor and
recipient combinations. However, reliable clinical
thresholds are not available yet, and multiple defi-
nitions for extended or high-risk liver grafts exist [3].
Of note, DCD livers with limited donor warm ische-
mia and relatively low age can achieve excellent
outcomes without any additional perfusion tech-
nique (60 years donor age,  20-min functional
donor warm ischemia,  6h cold ischemia, 5%
macrosteatosis).
In contrast, we would also classify DBD livers
older than 80 years, or DBD livers with more than
20% of macrosteatosis to the group of ‘ECD livers’,
and suggest to perform ex-vivo machine perfusion
preservation in those livers (Fig. 4).
In the future, machine perfusion techniques
will, therefore, enable physicians to accept more
risky allografts (overextended DCD). To promote
a universal application of HMP, the benefits should
be assessed objectively and compared to other per-
fusion approaches.
CONCLUSION AND FUTURE ASPECTS
Machine perfusion receives currently high interest
in the transplant community, as many organs carry
additional injury. Convincing machine perfusion
technologies should offer true repair of damaged
organs, should allow to measure metabolic function
before implantation, and should potentially pro-
long well tolerated preservation for up to 12h to
address logistic hurdles. At the same time, however,
perfusion technology needs to be as simple and
affordable as possible with utmost benefit compared
to cold storage. Current and future perfusion tech-
nologies should be evaluated and compared based
on these criteria. An optimized perfusion approach
is likely to be widely accepted by many transplant
Machine perfusion of organs
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programs with high consequences on organ supply
and outcome.
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